Determining liver toxicity of an agent using metabolite biomarkers
View Patent ↗The present invention provides various biomarkers for hepatotoxicity and various methods of using the biomarkers Some of the biomarkers within the scope of this invention are cholate, glycochenodeoxycholate, glycocholate, taurine, 3-hyroxy-2-ethylpropionate, 4-imidazoleacetate, tyramine, anthranilate, 2′-deoxycytidine, N-acetyl aspartate (NAA), beta-hydroxy-hexanoate, and sarcosine (N-methylglycine) The methods of using the biomarkers include exposing a first hepatocyte culture to a test agent and comparing the levels of the one or more biomarkers obtained in the first hepatocyte culture to the levels of the one or more biomarkers obtained in a second hepatocyte culture without the test agent, where differential levels of the one or more biomarkers in the first hepatocyte culture as compared to the levels in the second hepatocyte culture is indicative of the test agent being a hepatotoxicant.
1. A method of aiding in predicting the effect of an agent on liver function in a subject, comprising:
administering a test agent to a subject;
measuring levels of all of the following biomarkers: 4-ethylphenylsulfate, 1,5-anhydroglucitol (1,5-AG), 10-nonadecenoate (19:1n9), 2-(4-hydroxyphenyl)propionate, 2′deoxycytidine, 2-methylbutyrylglycine, 3-(4-hydroxyphenyl)lactate, 3-dehydrocholate, 3-hydroxy-2-ethylpropionate,4-hydroxybutyrate (GHB), 4-imidazoleacetate, 4-vinylphenolsulfate, 5-hydroxyhexanoate, alpha-ketoglutarate, anthranilate, beta-hydroxyisovalerate, catechol sulfate, cholate, citrate, dimethylglycine, glycocholate, lactate, malate, mannose, N-acetylaspartate (NAA), p-cresol sulfate, phenol sulfate, phenyllactate (PLA), pyroglutamine, sarcosine (N-methylglycine), succinate, taurine, taurocholate, threonine, trans-4-hydroxyproline, tyramine, 5-oxoproline, gamma-glutamylalanine, gamma-glutamylleucine, gamma-glutamylphenylalanine, gamma-glutamylthreonine, gamma-muricholate, glycochenodeoxycholate, glycodeoxycholate, gulono-1,4-lactone, N4-acetylcytidine, opthalmate, pantothenate, tauro-beta-muricholate, taurochenodeoxycholate, taurocholenate sulfate, taurolithocholate 3-sulfate, 1-docosahexaenoylglycerol (1-monodocosahexaenoin), 2-aminobutyrate, 2′-deoxyinosine, 3-aminoisobutyrate, 7-alpha-hydroxycholesterol, acetylcarnitine, alpha-tocopherol, carnitine, cystathionine, cysteine, cysteinylglycine, diohomo-linoleate (20:2n6), eicosenoate (20:1n9 or 11), gamma-glutamylisoleucine, gamma-glutamylvaline, glucarate (saccharate), glucose-6-phosphate (G6P), glucuronate, glycerate, homoserine (homoserine lactone), hypotaurine, hypoxanthine, isobutyrylcarnitine, N1-methyladenosine, N-acetylserine, pentadecanoate (15:0), propionylcarnitine, taurodeoxycholate, taurolithocholate, xanthine, and xylitol in a biological sample obtained from the subject; and
comparing the levels of the biomarkers in the sample to hepatotoxicity-positive and/or hepatotoxicity-negative reference levels of the biomarkers in order to predict the effect of the test agent on liver function in the subject.
2. The method of claim 1 , wherein the subject is a mammal.
3. The method of claim 2 , wherein the subject is a rat.
4. A method of aiding in predicting the effect of a test agent on liver function in a subject, comprising measuring levels of all of the following biomarkers: 4-ethylphenylsulfate, 1,5-anhydroglucitol (1,5-AG), 2-(4-hydroxyphenyl)propionate, 2′deoxycytidine, 2-methylbutyrylglycine, 3-(4-hydroxyphenyl)lactate, 3-dehydrocholate, 3-hydroxy-2-ethylpropionate, 4-hydroxybutyrate (GHB), 4-imidazoleacetate, 4-vinylphenol sulfate, 5-hydroxyhexanoate, alpha-ketoglutarate, anthranilate, beta-hydroxyisovalerate, catechol sulfate, cholate, citrate, dimethylglycine, glycocholate, lactate, malate, mannose, N-acetylaspartate (NAA), p-cresol sulfate, phenol sulfate, phenyllactate (PLA), pyroglutamine, sarcosine (N-methylglycine), succinate, taurine, taurocholate, threonine, trans-4-hydroxyproline, and tyramine in a urine sample obtained from a subject to whom a test agent has been administered, and
comparing the levels of the biomarkers in the sample to hepatotoxicity-positive and/or hepatotoxicity-negative reference levels of the biomarkers in order to predict the effect of the test agent on liver function in the subject.
5. The method of claim 4 , wherein a decrease in the level of 2′-deoxycytidine, 2-methylbutyrylglycine, 4-ethvlphenylsulfate, 4-vinylphenol sulfate, alpha-ketoglutarate, catechol sulfate, malate, p-cresol sulfate, phenol sulfate, and tyramine and an increase in the level of 3-(4-hydroxyphenyl)lactate, cholate, phenyllactate (PLA), pyroglutamine, and threonine is indicative of necrosis of the liver in the subject.
6. The method of claim 4 , wherein an increase in the level of threonine, cholate, and taurocholate and a decrease in the level of 2-(4-hydroxyphenyl)propionate, 4-ethylphenylsulfate, 4-vinylphenolsulfate, 5-hydroxyhexanoate, alpha ketoglutarate, anthranilate, beta-hydroxyisovalerate, catechol sulfate, citrate, dimethylglycine, lactate, malate, N-acetylaspartate (NAA), sarcosine (N-methylglycine), and succinate is indicative of cholestasis and/or steatosis of the liver in the subject.
7. The method of claim 4 , wherein an increase in the level of 4-imidazoleacetate, cholate, and pyroglutamine is indicative of damage to liver function in a human subject.
8. A method of aiding in predicting the effect of a test agent on liver function in a subject, comprising measuring levels of all of the following biomarkers: 3-dehydrocholate, 5-oxoproline, cholate, gamma-glutamylalanine, gamma-glutamylleucine, gamma-glutamylphenylalanine, gamma-glutamylthreonine, gamma-muricholate, glycochenodeoxycholate, glycocholate, glycodeoxycholate, gulono-1,4-lactone, N4-acetylcytidine, opthalmate, pantothenate, tauro-beta-muricholate, taurochenodeoxycholate, taurocholate, taurocholenate sulfate, taurolithocholate 3-sulfate, and trans-4-hydroxyproline in a plasma sample obtained from a subject to whom a test agent has been administered, and
comparing the levels of the biomarkers in the sample to hepatotoxicity-positive and/or hepatotoxicity-negative reference levels of the biomarkers in order to predict the effect of the test agent on liver function in the subject.
9. The method of claim 8 , wherein a decrease in the level of trans-4-hydroxyproline and an increase in the level of 3-dehydrocholate, 5-oxoproline, cholate, glycochenodeoxycholate , glycocholate, glycodeoxycholate, gulono-1,4-lactone, and opthalmate is indicative of necrosis of the liver in the subject.
10. The method of claim 8 , wherein an increase in the level of gamma-glutamylleucine, gamma-glutamylphenylalanine, taurocholate, taurochenodeoxycholate, taurocholenate sulfate, and N4-acetylcytidine is indicative of cholestasis and/or steatosis of the liver in the subject.
11. The method of claim 8 , wherein an increase in the level of glycocholate and glycochenodeoxycholate is indicative of damage to liver function in a human subject.
12. A method of aiding in predicting the effect of a test agent on liver function in a subject, comprising measuring the levels of all of the following biomarkers: 10-nonadecenoate (19:1n9), 1-docosahexaenoylglycerol (1-monodocosahexaenoin), 2-aminobutyrate, 2′-deoxyinosine, 3-aminoisobutyrate, 4-hydroxybutyrate (GHB), 7-alpha-hydroxycholesterol, acetylcarnitine, alpha-tocopherol, carnitine, cystathionine, cysteine, cysteinylglycine, diohomo-linoleate (20:2n6), eicosenoate (20:1n9 or 11), gamma-glutamylisoleucine, gamma-glutamylleucine, gamma-glutamylvaline, glucarate (saccharate), glucose-6-phosphate (G6P), glucuronate, glycerate, glycochenodeoxycholate, glycocholate, glycodeoxycholate, gulono-1,4-lactone, homoserine (homoserine lactone), hypotaurine, hypoxanthine, isobutyrylcarnitine, N1-methyladenosine, N-acetylserine, opthalmate, pentadecanoate (15:0), propionylcarnitine, taurine, taurocholate, taurocholate sulfate, taurodeoxycholate, taurolithocholate, xanthine, and xylitol in a liver tissue sample obtained from a subject to whom a test agent has been administered, and
comparing the levels of the biomarkers in the sample to hepatotoxicity-positive and/or hepatotoxicity-negative reference levels of the biomarkers in order to predict the effect of the test agent on liver function in the subject.
13. The method of claim 12 , wherein a decrease in the level of 10-nonadecenoate (19:1n9), alpha-tocopherol, dihomo-linoleate (20:2n6), eicosenoate (20:1n9 or 11), hypotaurine, pentadecanoate (15:0), taurine, and xanthine and an increase in the level of 2-aminobutyrate, 2′-deoxyinosine, 3-aminoisobutyrate,4-hydroxybutyrate (GHB), 7-alpha-hydroxycholesterol, acetylcarnitine, cystathionine, cysteine, cysteinylglycine, gamma-glutamylvaline, gamma-glutamylleucine, gamma-glutamylisoleucine, glucarate (saccharate), glucose-6-phosphate (G6P), glycerate, glucuronate, glycochenodeoxycholate, glycocholate, gulono-1,4-lactone, hypoxanthine, N1-methyladenosine, N-acetylserine, and ophthalmate, is indicative of necrosis of the liver in the subject.
14. The method of claim 12 , wherein an increase in the level of carnitine, homoserine (homoserine lactone), and taurine is indicative of cholestasis and/or steatosis of the liver in the subject.
15. The method of claim 12 , wherein a decrease in the level of xanthine and an increase in the level of glucarate (saccharate) and xylitol is indicative of damage to liver function in a human subject.